US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Climb Bio, Inc.

News headline image
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio, Inc. Announces $110.0 Million Private Placement
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM
News headline image
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Tickers CLYM